<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03113942</url>
  </required_header>
  <id_info>
    <org_study_id>SPACE</org_study_id>
    <nct_id>NCT03113942</nct_id>
  </id_info>
  <brief_title>Study of Pomalidomide in Anal Cancer Precursors</brief_title>
  <acronym>SPACE</acronym>
  <official_title>Study of Pomalidomide in Anal Cancer Precursors (SPACE): a Phase 2 Study of Immunomodulation in People With Persistent HPV-associated High Grade Squamous Intraepithelial Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kirby Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kirby Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single centre open label phase II trial to determine the antitumor efficacy of the
      oral immunomodulatory agent pomalidomide in persistent human papillomavirus (HPV) -associated
      high grade squamous intra-epithelial lesions (HSIL) in patients with and without human
      immunodeficiency virus (HIV) infection.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 14, 2017</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open label, phase 2 trial, single-arm</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Histological High Grade Squamous Intraepithelial Lesions (HSIL) clearance at 6 months of therapy</measure>
    <time_frame>6 months</time_frame>
    <description>Histological high grade squamous intra-epithelial lesion clearance</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>incidence of grade 3 and 4 adverse events and therapy delays (tolerability)</measure>
    <time_frame>6 months</time_frame>
    <description>incidence of grade 3 and 4 adverse events and therapy delays (tolerability)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of subjects completing of full six month course</measure>
    <time_frame>6 months</time_frame>
    <description>number of subjects completing of full six month course (feasibility of polidamide in this setting)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>effect of pomalidomide on self-reported health related quality of life and cancer anxiety during and after therapy</measure>
    <time_frame>6 months</time_frame>
    <description>individual patient change in quality of life questionnaire (SF12) from baseline to mid therapy and end therapy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>High Grade Squamous Intra-epithelial Lesion (HSIL)</condition>
  <arm_group>
    <arm_group_label>Pomalidomide group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open label - all participants will receive pomalidomide 2mg orally once a day for 6 cycles (21 days on treatment and a 7 day rest period constitutes a cycle).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pomalidomide 2 MG Oral Capsule [Pomalyst]</intervention_name>
    <description>Pomalidomide is an oral immunomodulatory derivative of thalidomide. Thalidomide and its derivatives are small molecules with broad effects on immune activation, including T-cell activation and responsiveness. Pomalidomide augments T cell responsiveness and proliferation by several mechanisms, many mediated by transcriptional regulation downstream of its primary target, cereblon. Effects include increased production of IL-2 and interferon-γ (IFN-γ), enhanced CD4+ and CD8+ T cell co-stimulation.</description>
    <arm_group_label>Pomalidomide group</arm_group_label>
    <other_name>pomalidomide</other_name>
    <other_name>Pomalyst</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Persistent high grade squamous intra-epithelial lesion (HSIL) which must meet all of
             the following criteria:

             i. Pathologically confirmed grade 2 or 3 AIN demonstrated by high resolution anoscopy
             with grade on each occasion re-confirmed at screening by nominated study pathologist
             from Douglas Hanly Moir (DHM) (pathology case review to be conducted prior to
             enrolment) ii. Lesion must have been visualised on at least three sequential occasions
             over at least 12 months, including the pre enrolment screening high resolution
             anoscopy (HRA).

             iii. Lesion must have persistent geographical characteristics consistent with a single
             lesion observed over time (as defined in the Manual of Operations).

          2. No history of thromboembolic disease

          3. No evidence of anal cancer or Superficially Invasive Squamous Cell Carcinoma of the
             Anus (SISCCA)

          4. Willingness to use appropriate contraception (including refraining from sperm
             donation)

          5. Age 18 years or older

          6. Provision of written informed consent

             In addition, for subjects with HIV:

          7. Adherence to a stable suppressive antiretroviral therapy (ART) regimen, unchanged for
             at least two months

          8. CD4+ count ≥ 200 cells/µl

          9. HIV viral load &lt; 200 copies/mL for at least six months

        Exclusion Criteria:

          1. Absolute neutrophil count (ANC) &lt;1000 cells/μL

          2. Haemoglobin &lt;10.0 g/dL

          3. Platelet count &lt;75,000 cells/μL

          4. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) &gt; three times upper
             limit of normal

          5. Calculated or measured creatinine clearance (CLCr) ≤ 50 mL/min (calculated by
             Cockcroft-Gault formula)

          6. Patients with significant cardiac dysfunction including congestive heart failure, NY
             Heart Association Class II; Myocardial infarction within 12 months of starting study;
             unstable of poorly controlled angina

          7. Current pregnancy or breastfeeding

          8. Any condition not already outlined above which, in the opinion of the clinical
             investigator, would place the subject at risk if they participated or would jeopardise
             adherence or follow up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mark Polizzotto, MD</last_name>
    <phone>+61 02 9385 0900</phone>
    <email>mpolizzotto@kirby.unsw.edu.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Griselda Buckland</last_name>
    <phone>+61 02 9385 0900</phone>
    <email>gbuckland@kirby.unsw.edu.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St Vincent's Hospital</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Coordinator</last_name>
      <phone>02 8382 4976</phone>
      <email>david.ninham@svha.org.au</email>
    </contact>
    <investigator>
      <last_name>Mark Polizzotto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <reference>
    <citation>Muñoz N, Castellsagué X, de González AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine. 2006 Aug 31;24 Suppl 3:S3/1-10. Epub 2006 Jun 23. Review.</citation>
    <PMID>16949995</PMID>
  </reference>
  <reference>
    <citation>Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine. 2006 Aug 31;24 Suppl 3:S3/11-25. Review.</citation>
    <PMID>16949997</PMID>
  </reference>
  <reference>
    <citation>World Health Organization International Agency for Reseach on Cancer. IARC Monograph on the Evaluation of Carcinogenic Risks to Humans: Volume 90, Human Papillomavirus. World Health Organization, Geneva 2007.</citation>
  </reference>
  <reference>
    <citation>Machalek DA, Poynten M, Jin F, Fairley CK, Farnsworth A, Garland SM, Hillman RJ, Petoumenos K, Roberts J, Tabrizi SN, Templeton DJ, Grulich AE. Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis. Lancet Oncol. 2012 May;13(5):487-500. doi: 10.1016/S1470-2045(12)70080-3. Epub 2012 Mar 23. Review.</citation>
    <PMID>22445259</PMID>
  </reference>
  <reference>
    <citation>Palefsky JM. Anal cancer prevention in HIV-positive men and women. Curr Opin Oncol. 2009 Sep;21(5):433-8. doi: 10.1097/CCO.0b013e32832f511a. Review.</citation>
    <PMID>19587592</PMID>
  </reference>
  <reference>
    <citation>Grulich AE, Poynten IM, Machalek DA, Jin F, Templeton DJ, Hillman RJ. The epidemiology of anal cancer. Sex Health. 2012 Dec;9(6):504-8. doi: 10.1071/SH12070.</citation>
    <PMID>22958581</PMID>
  </reference>
  <reference>
    <citation>Petoumenos K, van Leuwen MT, Vajdic CM, Woolley I, Chuah J, Templeton DJ, Grulich AE, Law MG; Australian HIV Observational Database. Cancer, immunodeficiency and antiretroviral treatment: results from the Australian HIV Observational Database (AHOD). HIV Med. 2013 Feb;14(2):77-84. doi: 10.1111/j.1468-1293.2012.01038.x. Epub 2012 Aug 30.</citation>
    <PMID>22934689</PMID>
  </reference>
  <reference>
    <citation>Yarchoan R, Tosato G, Little RF. Therapy insight: AIDS-related malignancies--the influence of antiviral therapy on pathogenesis and management. Nat Clin Pract Oncol. 2005 Aug;2(8):406-15; quiz 423. Review.</citation>
    <PMID>16130937</PMID>
  </reference>
  <reference>
    <citation>Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB 3rd, Thomas CR Jr, Mayer RJ, Haddock MG, Rich TA, Willett C. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA. 2008 Apr 23;299(16):1914-21. doi: 10.1001/jama.299.16.1914.</citation>
    <PMID>18430910</PMID>
  </reference>
  <reference>
    <citation>Moscicki AB, Schiffman M, Kjaer S, Villa LL. Chapter 5: Updating the natural history of HPV and anogenital cancer. Vaccine. 2006 Aug 31;24 Suppl 3:S3/42-51. Epub 2006 Jun 23. Review.</citation>
    <PMID>16950017</PMID>
  </reference>
  <reference>
    <citation>Tong WW, Shepherd K, Garland S, Meagher A, Templeton DJ, Fairley CK, Jin F, Poynten IM, Zaunders J, Hillman RJ, Grulich AE, Kelleher AD, Carr A; Study of the Prevention of Anal Cancer (SPANC) team. Human papillomavirus 16-specific T-cell responses and spontaneous regression of anal high-grade squamous intraepithelial lesions. J Infect Dis. 2015 Feb 1;211(3):405-15. doi: 10.1093/infdis/jiu461. Epub 2014 Aug 19.</citation>
    <PMID>25139018</PMID>
  </reference>
  <reference>
    <citation>Quach H, Ritchie D, Stewart AK, Neeson P, Harrison S, Smyth MJ, Prince HM. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia. 2010 Jan;24(1):22-32. doi: 10.1038/leu.2009.236. Epub 2009 Nov 12. Review.</citation>
    <PMID>19907437</PMID>
  </reference>
  <reference>
    <citation>Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y, Yamaguchi Y, Handa H. Identification of a primary target of thalidomide teratogenicity. Science. 2010 Mar 12;327(5971):1345-50. doi: 10.1126/science.1177319.</citation>
    <PMID>20223979</PMID>
  </reference>
  <reference>
    <citation>Görgün G, Calabrese E, Soydan E, Hideshima T, Perrone G, Bandi M, Cirstea D, Santo L, Hu Y, Tai YT, Nahar S, Mimura N, Fabre C, Raje N, Munshi N, Richardson P, Anderson KC. Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood. 2010 Oct 28;116(17):3227-37. doi: 10.1182/blood-2010-04-279893. Epub 2010 Jul 22.</citation>
    <PMID>20651070</PMID>
  </reference>
  <reference>
    <citation>Lentzsch S, LeBlanc R, Podar K, Davies F, Lin B, Hideshima T, Catley L, Stirling DI, Anderson KC. Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo. Leukemia. 2003 Jan;17(1):41-4.</citation>
    <PMID>12529658</PMID>
  </reference>
  <reference>
    <citation>Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, Roth M, Vaughn M, Knight J, Wallace P, Czuczman MS. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol. 2008 Jan;140(1):36-45. Epub 2007 Nov 9.</citation>
    <PMID>17995965</PMID>
  </reference>
  <reference>
    <citation>Verhelle D, Corral LG, Wong K, Mueller JH, Moutouh-de Parseval L, Jensen-Pergakes K, Schafer PH, Chen R, Glezer E, Ferguson GD, Lopez-Girona A, Muller GW, Brady HA, Chan KW. Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer Res. 2007 Jan 15;67(2):746-55.</citation>
    <PMID>17234786</PMID>
  </reference>
  <reference>
    <citation>Zhu D, Corral LG, Fleming YW, Stein B. Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. Cancer Immunol Immunother. 2008 Dec;57(12):1849-59. doi: 10.1007/s00262-008-0512-7. Epub 2008 Apr 8.</citation>
    <PMID>18392823</PMID>
  </reference>
  <reference>
    <citation>Shalapour S, Zelmer A, Pfau M, Moderegger E, Costa-Blechschmidt C, van Landeghem FK, Taube T, Fichtner I, Bührer C, Henze G, Seeger K, Wellmann S. The thalidomide analogue, CC-4047, induces apoptosis signaling and growth arrest in childhood acute lymphoblastic leukemia cells in vitro and in vivo. Clin Cancer Res. 2006 Sep 15;12(18):5526-32.</citation>
    <PMID>17000689</PMID>
  </reference>
  <reference>
    <citation>Escoubet-Lozach L, Lin IL, Jensen-Pergakes K, Brady HA, Gandhi AK, Schafer PH, Muller GW, Worland PJ, Chan KW, Verhelle D. Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. Cancer Res. 2009 Sep 15;69(18):7347-56. doi: 10.1158/0008-5472.CAN-08-4898. Epub 2009 Sep 8.</citation>
    <PMID>19738071</PMID>
  </reference>
  <reference>
    <citation>Pal R, Monaghan SA, Hassett AC, Mapara MY, Schafer P, Roodman GD, Ragni MV, Moscinski L, List A, Lentzsch S. Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia. Blood. 2010 Jan 21;115(3):605-14. doi: 10.1182/blood-2009-05-221077. Epub 2009 Nov 25.</citation>
    <PMID>19965623</PMID>
  </reference>
  <reference>
    <citation>Polizzotto MN, Sereti I, Uldrick TS, et al. Pomalidomide induces expansion of activated and central memory CD4 and CD8 T-cells in vivo in patients with and without HIV infection. American Society of Hematology Annual Meeting, San Francisco 2014.</citation>
  </reference>
  <reference>
    <citation>Polizzotto MN, Uldrick TS, Wyvill KM, Aleman K, Peer CJ, Bevans M, Sereti I, Maldarelli F, Whitby D, Marshall V, Goncalves PH, Khetani V, Figg WD, Steinberg SM, Zeldis JB, Yarchoan R. Pomalidomide for Symptomatic Kaposi's Sarcoma in People With and Without HIV Infection: A Phase I/II Study. J Clin Oncol. 2016 Dec;34(34):4125-4131. Epub 2016 Oct 31.</citation>
    <PMID>27863194</PMID>
  </reference>
  <reference>
    <citation>Machalek DA, Grulich AE, Hillman RJ, Jin F, Templeton DJ, Tabrizi SN, Garland SM, Prestage G, McCaffery K, Howard K, Tong W, Fairley CK, Roberts J, Farnsworth A, Poynten IM; SPANC Study Team. The Study of the Prevention of Anal Cancer (SPANC): design and methods of a three-year prospective cohort study. BMC Public Health. 2013 Oct 9;13:946. doi: 10.1186/1471-2458-13-946.</citation>
    <PMID>24107134</PMID>
  </reference>
  <reference>
    <citation>Richel O, de Vries HJ, van Noesel CJ, Dijkgraaf MG, Prins JM. Comparison of imiquimod, topical fluorouracil, and electrocautery for the treatment of anal intraepithelial neoplasia in HIV-positive men who have sex with men: an open-label, randomised controlled trial. Lancet Oncol. 2013 Apr;14(4):346-53. doi: 10.1016/S1470-2045(13)70067-6. Epub 2013 Mar 15.</citation>
    <PMID>23499546</PMID>
  </reference>
  <reference>
    <citation>POMALYST® (pomalidomide) capsules Product Information. Department of Health Therapeutic Goods Administration (TGA) April 2016. https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf accessed 23 Nov 2016.</citation>
  </reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2017</study_first_submitted>
  <study_first_submitted_qc>April 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2017</study_first_posted>
  <last_update_submitted>June 22, 2017</last_update_submitted>
  <last_update_submitted_qc>June 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anus Neoplasms</mesh_term>
    <mesh_term>Squamous Intraepithelial Lesions of the Cervix</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pomalidomide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

